163 related articles for article (PubMed ID: 15153470)
1. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL.
Lyman MA; Aung S; Biggs JA; Sherman LA
J Immunol; 2004 Jun; 172(11):6558-67. PubMed ID: 15153470
[TBL] [Abstract][Full Text] [Related]
2. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice.
Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA
J Immunol; 2005 Mar; 174(5):2563-72. PubMed ID: 15728462
[TBL] [Abstract][Full Text] [Related]
3. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy.
Speiser DE; Miranda R; Zakarian A; Bachmann MF; McKall-Faienza K; Odermatt B; Hanahan D; Zinkernagel RM; Ohashi PS
J Exp Med; 1997 Aug; 186(5):645-53. PubMed ID: 9271580
[TBL] [Abstract][Full Text] [Related]
4. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
5. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
6. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
7. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
8. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
Dumortier H; van Mierlo GJ; Egan D; van Ewijk W; Toes RE; Offringa R; Melief CJ
J Immunol; 2005 Jul; 175(2):855-63. PubMed ID: 16002683
[TBL] [Abstract][Full Text] [Related]
9. Defects in the acquisition of tumor-killing capability of CD8+ cytotoxic T cells in streptozotocin-induced diabetic mice.
Chen SC; Su YC; Lu YT; Ko PC; Chang PY; Lin HJ; Ho HN; Lai YP
PLoS One; 2014; 9(11):e109961. PubMed ID: 25390652
[TBL] [Abstract][Full Text] [Related]
10. Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts.
Vizler C; Bercovici N; Heurtier A; Pardigon N; Goude K; Bailly K; Combadière C; Liblau RS
J Immunol; 2000 Dec; 165(11):6314-21. PubMed ID: 11086068
[TBL] [Abstract][Full Text] [Related]
11. Characterization of CD8+ T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas.
Nugent CT; Morgan DJ; Biggs JA; Ko A; Pilip IM; Pamer EG; Sherman LA
J Immunol; 2000 Jan; 164(1):191-200. PubMed ID: 10605011
[TBL] [Abstract][Full Text] [Related]
12. Naive CD8+ T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells.
Wang B; Maile R; Greenwood R; Collins EJ; Frelinger JA
J Immunol; 2000 Feb; 164(3):1216-22. PubMed ID: 10640733
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors.
Otahal P; Knowles BB; Tevethia SS; Schell TD
J Immunol; 2007 Nov; 179(10):6686-95. PubMed ID: 17982058
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific Treg impair CD8(+) T-cell priming by blocking early T-cell expansion.
Chappert P; Leboeuf M; Rameau P; Lalfer M; Desbois S; Liblau RS; Danos O; Davoust JM; Gross DA
Eur J Immunol; 2010 Feb; 40(2):339-50. PubMed ID: 19877007
[TBL] [Abstract][Full Text] [Related]
15. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
Asnagli H; Schmitt-Verhulst AM; Guimezanes A
J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
[TBL] [Abstract][Full Text] [Related]
16. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
17. Ly49D engagement on T lymphocytes induces TCR-independent activation and CD8 effector functions that control tumor growth.
Merck E; Voyle RB; MacDonald HR
J Immunol; 2009 Jan; 182(1):183-92. PubMed ID: 19109149
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cytokine-driven functional differentiation of CD8 T cells by suppressor of cytokine signaling 1 controls autoimmunity and preserves their proliferative capacity toward foreign antigens.
Ramanathan S; Dubois S; Gagnon J; Leblanc C; Mariathasan S; Ferbeyre G; Rottapel R; Ohashi PS; Ilangumaran S
J Immunol; 2010 Jul; 185(1):357-66. PubMed ID: 20519645
[TBL] [Abstract][Full Text] [Related]
19. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
20. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
